A new study backs up a suggestion that high dosages of aspirin may interfere with AstraZeneca's heart drug Brilinta, offering a possible explanation for disappointing results from a trial among patients in North America. The drug is approved in Europe, but awaits the OK from U.S. regulators, partly because of this geographical disparity in results. Story | Report